NASDAQ:GCTK GlucoTrack (GCTK) Stock Price, News & Analysis → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free GCTK Stock Alerts $0.72 +0.19 (+36.19%) (As of 04/17/2024 ET) Add Compare Share Share Today's Range$0.50▼$0.7250-Day Range$0.21▼$0.7252-Week Range$0.13▼$1.00Volume636,968 shsAverage Volume204,480 shsMarket Capitalization$19.13 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get GlucoTrack alerts: Email Address Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About GlucoTrack Stock (NASDAQ:GCTK)GlucoTrack, Inc., a medical device company, focuses on designing, developing, and commercializing non-invasive glucose monitoring devices for use by people with diabetes in the United States. It develops GlucoTrack, a non-invasive blood glucose monitor that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.Read More GCTK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GCTK Stock News HeadlinesApril 17, 2024 | finance.yahoo.comGlucoTrack, Inc. (GCTK)April 16, 2024 | globenewswire.comGLUCOTRACK ANNOUNCES EXPANSION OF ITS CONTINUOUS GLUCOSE MONITORING TECHNOLOGY TO EPIDURAL GLUCOSE MONITORINGApril 18, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.April 2, 2024 | globenewswire.comGLUCOTRACK ANNOUNCES INCREASED SENSOR LONGEVITY FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITORMarch 13, 2024 | nz.finance.yahoo.comUK mortgage arrears rise 50% amid high interest ratesMarch 12, 2024 | globenewswire.comGLUCOTRACK EXPANDS LEADERSHIP TEAM WITH NEW VICE PRESIDENT OF QUALITYFebruary 27, 2024 | finanznachrichten.deGlucoTrack, Inc.: Glucotrack Selects Cirtec Medical As Manufacturer For Its Implantable Continuous Blood Glucose MonitorFebruary 27, 2024 | globenewswire.comGLUCOTRACK SELECTS CIRTEC MEDICAL AS MANUFACTURER FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITORApril 18, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.February 13, 2024 | msn.comGlucotrack names Luis Malavé board chairFebruary 13, 2024 | finance.yahoo.comGLUCOTRACK ANNOUNCES THE APPOINTMENT OF LUIS MALAVÉ TO CHAIR OF THE BOARD OF DIRECTORSJanuary 3, 2024 | finanznachrichten.deGlucoTrack, Inc.: Glucotrack Announces Early Accuracy Data For Its Implantable Continuous Glucose MonitorJanuary 2, 2024 | msn.comGlucoTrack stock jumps 13% on preclinical update for glucose monitorJanuary 2, 2024 | finance.yahoo.comGLUCOTRACK ANNOUNCES EARLY ACCURACY DATA FOR ITS IMPLANTABLE CONTINUOUS GLUCOSE MONITORDecember 1, 2023 | finanznachrichten.deGlucoTrack, Inc.: Glucotrack Announces 180-day Extension To Regain Compliance With Nasdaq Minimum Bid Price RequirementDecember 1, 2023 | msn.comNasdaq grants additional 180 days to Glucotrack to regain complianceNovember 30, 2023 | finance.yahoo.comGLUCOTRACK ANNOUNCES 180-DAY EXTENSION TO REGAIN COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENTNovember 13, 2023 | finance.yahoo.comGLUCOTRACK ANNOUNCES SHAREHOLDER UPDATENovember 10, 2023 | msn.comWhy Wynn Resorts Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day SessionOctober 12, 2023 | finance.yahoo.comGLUCOTRACK ANNOUNCES PRECLINICAL TESTING WITH IMPLANTABLE CONTINUOUS GLUCOSE MONITORAugust 31, 2023 | finance.yahoo.comGLUCOTRACK ANNOUNCES THE APPOINTMENT OF ERIN CARTER TO BOARD OF DIRECTORSAugust 28, 2023 | finance.yahoo.comGLUCOTRACK ANNOUNCES NEW VP OF MARKETINGAugust 24, 2023 | finance.yahoo.comIntegrity Foundation Launches Impactful Nationwide Community Initiative with State-of-the-Art Playground Build in NebraskaAugust 23, 2023 | ftw.usatoday.comBig 12 partners with U.S. Integrity to prevent prohibited sports betting: Here's what it meansAugust 22, 2023 | theguardian.comHead of Athletics Integrity Unit takes aim at doping policies of other sportsAugust 16, 2023 | benzinga.comStarlizard Integrity Services identifies 79 suspicious football matches played globally in first half of 2023August 15, 2023 | markets.businessinsider.comFleetPride Acquires Integrity Fleet Services, Expanding Its Service Footprint in the Commercial Vehicle Independent AftermarketSee More Headlines Receive GCTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GlucoTrack and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/17/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:GCTK CUSIPN/A CIK1506983 Webwww.glucotrack.com Phone(201) 842-7715Fax972-8675-7850Employees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,100,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-172.38% Return on Assets-127.42% Debt Debt-to-Equity Ratio0.06 Current Ratio3.22 Quick Ratio3.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book4.77Miscellaneous Outstanding Shares26,760,000Free Float22,020,000Market Cap$19.13 million OptionableNot Optionable Beta0.29 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Paul V. Goode Ph.D. (Age 55)Chief Executive Officer Comp: $225kMr. Mark Tapsak Ph.D. (Age 55)Vice President of Technology Comp: $165kMs. Drinda Benjamin (Age 48)Vice President of Marketing Mr. James P. Thrower Ph.D. (Age 54)Vice President of Engineering Comp: $230kMr. Avner Gal MBA (Age 70)MSc.EE, Co-Founder, Chairman Emeritus, Consultant and Member of Scientific & Clinical Advisory Board Comp: $187.39kMr. David Malka BA (Age 59)Co-Founder Comp: $191.86kMr. James S. Cardwell (Age 63)Chief Financial Officer More ExecutivesKey CompetitorsMicrobot MedicalNASDAQ:MBOTBioSig TechnologiesNASDAQ:BSGMNEXGELNASDAQ:NXGLMeihua International Medical TechnologiesNASDAQ:MHUAPetVivoNASDAQ:PETVView All Competitors GCTK Stock Analysis - Frequently Asked Questions How have GCTK shares performed in 2024? GlucoTrack's stock was trading at $0.2615 at the beginning of the year. Since then, GCTK shares have increased by 173.4% and is now trading at $0.7150. View the best growth stocks for 2024 here. Are investors shorting GlucoTrack? GlucoTrack saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 98,100 shares, an increase of 1,157.7% from the March 15th total of 7,800 shares. Based on an average trading volume of 110,700 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.5% of the shares of the stock are short sold. View GlucoTrack's Short Interest. When is GlucoTrack's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our GCTK earnings forecast. How were GlucoTrack's earnings last quarter? GlucoTrack, Inc. (NASDAQ:GCTK) released its earnings results on Thursday, March, 28th. The company reported ($0.10) earnings per share for the quarter. How do I buy shares of GlucoTrack? Shares of GCTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GCTK) was last updated on 4/18/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profits[Urgent!] Generational Wealth GameplanCrypto 101 MediaTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsBiden out June 13; Kamala won’t replace him?Paradigm PressUrgent alert: open this for a huge profit potentialTimothy SykesOptions trading has suddenly become more reliable.Eagle PublishingThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlucoTrack, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.